About Athena Countouriotis
Athena Countouriotis is a director at Iovance Biotherapeutics.
Form D filings name Athena Countouriotis as an executive officer and director at Avenzo Therapeutics.
Athena Countouriotis reports to the SEC as a director or officer of 8 public companies, including Biomarin Pharmaceutical (BMRN), Passage BIO (PASG) and Turning Point Therapeutics (TPTX).
Athena Countouriotis first appears on SEC filings in 2013.
Experience
This experience comes from SEC filings. The years are when the filings name Athena Countouriotis in the role, so the role may have started earlier or lasted longer.
II
Iovance Biotherapeutics, Inc.
Director
2019 – 2026 · Public company (IOVA)
BI
Biomarin Pharmaceutical Inc.
Director
2023 – 2026 · Public company (BMRN)
PI
Passage BIO, Inc.
Director
2020 – 2026 · Public company (PASG)
TI
Turning Point Therapeutics, Inc.
President & CEO, director
2019 – 2022 · Public company (TPTX)
CI
Cardiff Oncology, Inc.
Director
2017 – 2019 · Public company (CRDF)
AI
Adverum Biotechnologies, Inc.
SVP, Chief Medical Officer
2017 – 2018 · Public company (ADVM)
HI
Halozyme Therapeutics, Inc.
SVP and Chief Medical Officer
2015 – 2017 · Public company (HALO)
AC
Ambit Biosciences Corp.
Chief Medical Officer
2013 – 2014 · Public company (AMBI)
Key Colleagues at Startups
The people Athena Countouriotis works with at each company, as listed on that company's latest Form D.
Avenzo Therapeutics, Inc. · Form D, Sep 5, 2025
CG
Carl Gordon
Director
GN
Garry Nicholson
Director
PM
Patrick Machado
Director
JL
Judith Li
Director
PT
Paolo Tombesi
Executive officer
MH
Mohammad Hirmand
Executive officer
SG
Simeon George
Director
SL
Scott Lipman
Executive officer
BS
Brian Sun
Executive officer
JA
Jakob Dupont, M.D., M.A.
Director